Pfizer Inc. is initiating a Phase 2 trial for its drug etrasimod in children with moderate to severe ulcerative colitis, aiming to evaluate its efficacy and safety in this young patient population. The open-label, single-arm study will have participants treated for up to 52 weeks with an option for a long-term extension. This move expands etrasimod’s potential market and positions Pfizer against competitors like AbbVie and Johnson & Johnson in the inflammatory bowel disease space.
Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch
Pfizer Inc. is initiating a Phase 2 trial for its drug etrasimod in children with moderate to severe ulcerative colitis, aiming to evaluate its efficacy and safety in this young patient population. The open-label, single-arm study will have participants treated for up to 52 weeks with an option for a long-term extension. This move expands etrasimod’s potential market and positions Pfizer against competitors like AbbVie and Johnson & Johnson in the inflammatory bowel disease space.